Phase Ib/II Study of a Liposomal Formulation of Eribulin (E7389-LF) plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase Ib.

Hanae Ida Toshio Shimizu Makoto Nishino Yoshiaki Nakamura Shu Yazaki Yuki Katsuya Jun Sato Takafumi Koyama Satoru Iwasa Kazuki Sudo Shunsuke Kondo Kan Yonemori Kohei Shitara Satoshi Shiono Daiko Matsuoka Keisuke Yasuda Yohei Otake Takuya Suzuki Takao Takase Shuya Takashima Kohei Yamaguchi Taro Semba Noboru Yamamoto

Published in: Cancer research communications (2023)

This phase Ib part of a phase Ib/II study assessed the tolerability and activity of a liposomal formulation of eribulin (E7389-LF) plus nivolumab in 25 patients with advanced solid tumors. The combination was tolerable overall; 4 patients had a partial response. Vasculature and immune-related biomarker levels increased, suggesting vascular remodeling.

Keyphrases

end stage renal disease
drug delivery
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
open label
phase ii
drug induced